Abivax Joins CAC Mid 60 and SBF 120 Indices
Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) has recently celebrated a significant milestone as it joins the prestigious CAC Mid 60 and SBF 120 indices. This decision, announced following the annual review by Euronext Paris, is a testament to the company’s relentless pursuit of excellence in the biotechnology sector.
Understanding the Impact of Inclusion
This inclusion is scheduled to take effect after market close on a specified Friday in the near future. The CAC Mid 60 index focuses on mid-sized companies, while the SBF 120 index encompasses a broader selection of major French securities. Being part of these indices is expected to enhance Abivax’s visibility in the investment community, promoting greater accessibility for institutional investors and index-tracking funds.
Abivax's Commitment to Innovation
During the announcement, Marc de Garidel, CEO of Abivax, expressed his pride in the company's inclusion in these respected indices. He noted that this recognition underscores the financial markets' confidence in Abivax’s strategic goals and their execution capabilities. Furthermore, he hinted that this development would bolster the company's mission to deliver innovative therapies for patients battling chronic inflammatory diseases, while simultaneously delivering long-term value to shareholders.
The Vision Behind Abivax's Growth
Abivax is dedicated to the research and development of new therapies, specifically targeting chronic inflammatory diseases. With a strong foundation in scientific innovation and a global presence in both France and the United States, Abivax is at the forefront of medical advancements. The company's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials, focusing on treatment for moderately to severely active ulcerative colitis, making significant strides towards helping those with such conditions.
The Future of Abivax
As Abivax prepares for its next phase of growth, industry experts are keenly watching how the company will leverage its position within these key indices. With a solid growth strategy and innovative product pipeline, Abivax aims to help transform the lives of individuals suffering from chronic inflammation while establishing a robust market presence. Investors can look forward to what this new chapter holds for the company.
Engage with Abivax
Abivax encourages interested parties to learn more about their ongoing developments and research endeavors. For corporate inquiries and investor relations, individuals can reach out to:
Patrick Malloy
patrick.malloy@abivax.com
+1 847 987 4878
Frequently Asked Questions
What indices has Abivax been included in?
Abivax has joined the CAC Mid 60 and SBF 120 indices, which represent mid-sized and major securities listed on Euronext Paris.
When will the inclusion take effect?
The inclusion of Abivax in the indices will take effect after market close on a designated Friday soon.
What is Abivax focused on?
Abivax is focused on developing innovative therapeutics targeting chronic inflammatory diseases, particularly through its lead drug candidate, obefazimod.
How does this inclusion enhance Abivax's visibility?
Inclusion in these significant indices raises Abivax’s visibility among institutional investors and can broaden its investor base, facilitating easier access to its shares.
Who should I contact for investor relations at Abivax?
For inquiries, you can contact Patrick Malloy at patrick.malloy@abivax.com or reach him at +1 847 987 4878.
